AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 82 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $1,063,000 | +35.2% | 117,600 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $786,000 | +19.1% | 117,600 | -10.2% | 0.00% | 0.0% |
Q3 2020 | $660,000 | -37.7% | 131,025 | +0.0% | 0.00% | 0.0% |
Q2 2020 | $1,059,000 | +73.3% | 131,017 | +70.2% | 0.00% | 0.0% |
Q1 2020 | $611,000 | -2.7% | 77,000 | -7.5% | 0.00% | 0.0% |
Q4 2019 | $628,000 | +78.4% | 83,200 | -1.5% | 0.00% | – |
Q3 2019 | $352,000 | +44.3% | 84,500 | 0.0% | 0.00% | – |
Q2 2019 | $244,000 | +100.0% | 84,500 | 0.0% | 0.00% | – |
Q1 2019 | $122,000 | -44.0% | 84,500 | 0.0% | 0.00% | – |
Q4 2018 | $218,000 | -45.1% | 84,500 | -6.5% | 0.00% | -100.0% |
Q3 2018 | $397,000 | -35.6% | 90,401 | -10.0% | 0.00% | 0.0% |
Q2 2018 | $616,000 | -9.8% | 100,453 | +7.3% | 0.00% | 0.0% |
Q1 2018 | $683,000 | -1.4% | 93,638 | +10.8% | 0.00% | 0.0% |
Q4 2017 | $693,000 | -21.9% | 84,500 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $887,000 | -4.8% | 84,500 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $932,000 | +13.9% | 84,500 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $818,000 | – | 84,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Stonepine Capital Management, LLC | 985,210 | $10,345,000 | 6.10% |
Broadfin Capital, LLC | 3,568,122 | $37,465,000 | 5.54% |
JW Asset Management, LLC | 444,439 | $4,667,000 | 3.42% |
ARMISTICE CAPITAL, LLC | 1,688,000 | $17,724,000 | 2.09% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $38,383,000 | 1.73% |
FALCON POINT CAPITAL, LLC | 661,490 | $6,284,000 | 0.91% |
KNOTT DAVID M | 158,555 | $1,665,000 | 0.71% |
Perceptive Advisors | 3,098,010 | $32,530,000 | 0.62% |
Sio Capital Management, LLC | 91,413 | $960,000 | 0.50% |
HEARTLAND ADVISORS INC | 700,000 | $7,350,000 | 0.48% |